Curriculum Vitae

Joel Thompson, M.S.

Tannock Laboratory

Personal:

Address: Department of Internal Medicine

University of Kentucky

Room 563, Charles T. Wethington Building

900 S. Limestone St.

Lexington, KY 40536-0200

Cell: 859 539-6217

Email:

Education:

2010-: Graduate Student, Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY

2000-2003: M.S., Structural Biology, Department of Biological Sciences

Eastern Kentucky University, Richmond, KY

Mentor: William Farrah, PhD.

1993-1999 B.S., Biology, Department of Biological Sciences

University of Kentucky, Lexington, KY

Professional Experience:

2009-2010 Research Associate Senior- Tannock Lab, Department of Internal Medicine University of Kentucky College of Medicine, Lexington, KY

2007-2009 Research Analyst Senior- Tannock Lab, Department of Internal Medicine

University of Kentucky College of Medicine, Lexington, KY

2005-2007 Research Analyst- Tannock Lab, Department of Internal Medicine

University of Kentucky College of Medicine, Lexington, KY

2006-2010 Adjunct Faculty- Department of Natural Sciences, Division of Biological Sciences, Bluegrass Community and Technical College, Lexington, KY

2003-2004 Research Analyst- Mao Lab, Graduate Center for Nutritional Science

University of Kentucky College of Medicine, Lexington, KY

Research Interests:

Obesity and diabetes are associated with chronic inflammation which increases the risk of developing cardiovascular disease. It has been observed in both humans and mice that Serum Amyloid A (SAA), a biomarker of inflammation, is modestly increased in these disease states as well as others. SAA has been found in both human and mouse atherosclerotic lesions and has been shown to increase the size and LDL binding capacity of small matrix associated proteoglycans such as Biglycan and Perlecan. Recently SAA has been shown to play a causal role in the progression of atherosclerosis. The goal of my research is to examine the role SAA may play in the initiation of atherosclerosis, specifically the effect it may have on LDL retention in the vessel wall prior to fatty streak formation.

Publications:

1. De Beer, M.C., et al., Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2014. 34(2): p. 255-61.

2. Tang, T., et al., Prevention of TGFbeta induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice. J Lipid Res, 2013. 54(8): p. 2255-64.

3. Tang, T., et al., Decreased body fat, elevated plasma transforming growth factor-beta levels, and impaired BMP4-like signaling in biglycan-deficient mice. Connect Tissue Res, 2013. 54(1): p. 5-13.

4. King, V.L., et al., Serum amyloid A in atherosclerosis

Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner, Curr Opin Lipidol, 2011. 22(4): p. 302-7.

5. Thompson, J., et al., Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol, 2011. 179(3): p. 1179-87.

6. Taneja, D., et al., Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res, 2010. 51(6): p. 1464-70.

7. Wilson, P.G., et al., Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol, 2008. 173(6): p. 1902-10.

8. Huang, F., et al., Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res, 2008. 49(3): p. 521-30.

Abstracts:

1.  Joel Thompson, Patricia Wilson, Meghan Yoder, Kyle Brandewie, Nancy Webb, Lisa Tannock; Serum Amyloid A acts through TGF-b to increase atherosclerosis, ATVB, 2013

2.  Joel Thompson, Patricia Wilson, Kyle Brandewie, Nancy Webb, Lisa Tannock; Serum Amyloid A is proatherogenic. . ATVB, 2012

3.  Joel Thompson, Patricia Wilson, Christina Nelson, Kyle Brandewie, Nancy Webb, Lisa R. Tannock; Modest but chronic elevations of SAA contributes to atherogenesis. Southeast Lipid Research Conference, 2011

4.  Joel Thompson, Patricia Wilson, Christina Nelson, Kyle Brandewie, Nancy Webb, Lisa R. Tannock; Modest but chronic elevations of SAA may contribute causally to atherogenesis via induction of vascular biglycan contentandLDL retention. Barnstable Brown Diabetes and Obesity Research Day, 2011

5.  Joel Thompson, PG Wilson, C Nelson, LR Tannock; Neutralizing TGF-b Prevents SAA Up-regulation of Biglycan but Accelerates Atherosclerosis. Gordon Conference on Proteoglycans, 2010

6.  Joel Thompson, Patricia Wilson, Nancy Webb, Lisa R. Tannock; SAA is Pro-Atherogenic. Gill Cardiovascular Research Day, 2009

7.  Joel Thompson, Deepa Taneja, Patricia Wilson, Lisa R. Tannock; Diabetes Increases Renal Biglycan Content and Renal Lipid Accumulation. ASN 2006

8.  Joel Thompson, Deepa Taneja, Patricia Wilson, Lisa R. Tannock; Dietary Cholesterol Exacerbates Nephropathy in Diabetes. ATVB, 2006

9.  Joel Thompson, Raimund Pichler, Karin Bornfeldt, Lisa R. Tannock; Dietary Cholesterol Exacerbates Atherosclerosis and Nephropathy in Diabetes. Gill Cardiovascular Research Day, 2005

Honors:

2012 AHA Predoctoral Fellowship

2012 ATVB Travel award

2012 Barnstable Brown Diabetes and Obesity Research Day scientific presentation award, student category

2009 Elected to present a module on blood glucose and its effects on obesity and diabetes for UK College of Medicine’s first annual Legislative Mini Medical School.

2006 Gill Heart Institute, Cardiovascular Research Day,
Excellence in Scientific Presentation Award

2005 Gill Heart Institute, Cardiovascular Research Day,
Excellence in Scientific Presentation Award